Emeline Tabouret1, Philippe Metellus, Anthony Gonçalves, Benjamin Esterni, Emmanuelle Charaffe-Jauffret, Patrice Viens, Agnés Tallet. 1. APHM, Timone Hospital, Departement of Neuro-Oncology, Marseille, France (E.T.); L'institut Paoli-Calmettes, Department of Medical Oncology, Marseille, France (E.T., A.G.); APHM, Timone Hospital, Department of Neurosurgery, Marseille, France (P.M.); L'institut Paoli-Calmettes, Department of Biostatistics, Marseille, France (B.E.); UMR911, CRO2, Aix-Marseille Université, Marseille, France (P.M.); L'institut Paoli-Calmettes, Department of Anatomic Pathology, Marseille, France (E.C.-J.); L'institut Paoli-Calmettes, Department of Radiotherapy, Marseille, France (A.T.).
Abstract
BACKGROUND: Breast cancer (BC) is the second most common cause of brain metastases (BM). Optimal management of BM from BC is still debated. In an attempt to provide appropriate treatment and to assist with optimal patient selection, several specific prognostic classifications for BM from BC have been established. We evaluated the prognostic value and validity of the 6 proposed scoring systems in an independent population of BC patients with BM. METHODS: We retrospectively reviewed all consecutive BC patients referred to our institution for newly diagnosed BM between October 1995 and July 2011 (n = 149). Each of the 6 scores proposed for BM from BC (Sperduto, Niwinska, Park, Nieder, Le Scodan, and Claude) was applied to this population. The discriminative ability of each score was assessed using the Brier score and the C-index. Individual prognostic values of clinical and histological factors were analyzed using uni- and multivariate analyses. RESULTS: Median overall survival was 15.1 months (95% CI,11.5-18.7). Sperduto-GPA (P < .001), Nieder (P < .001), Park (P < .001), Claude (P < .001), Niwinska (P < .001), and Le Scodan (P = .034) scores all showed significant prognostic value. The Nieder score showed the best discriminative ability (C-index, 0.672; Brier score error reduction, 16.1%). CONCLUSION: The majority of prognostic scores were relevant for patients with BM from BC in our independent population, and the Nieder score seems to present the best predictive value but showed a relatively low positive predictive value. Thus, these results remain insufficient and challenge the routine use of these scoring systems.
BACKGROUND:Breast cancer (BC) is the second most common cause of brain metastases (BM). Optimal management of BM from BC is still debated. In an attempt to provide appropriate treatment and to assist with optimal patient selection, several specific prognostic classifications for BM from BC have been established. We evaluated the prognostic value and validity of the 6 proposed scoring systems in an independent population of BC patients with BM. METHODS: We retrospectively reviewed all consecutive BC patients referred to our institution for newly diagnosed BM between October 1995 and July 2011 (n = 149). Each of the 6 scores proposed for BM from BC (Sperduto, Niwinska, Park, Nieder, Le Scodan, and Claude) was applied to this population. The discriminative ability of each score was assessed using the Brier score and the C-index. Individual prognostic values of clinical and histological factors were analyzed using uni- and multivariate analyses. RESULTS: Median overall survival was 15.1 months (95% CI,11.5-18.7). Sperduto-GPA (P < .001), Nieder (P < .001), Park (P < .001), Claude (P < .001), Niwinska (P < .001), and Le Scodan (P = .034) scores all showed significant prognostic value. The Nieder score showed the best discriminative ability (C-index, 0.672; Brier score error reduction, 16.1%). CONCLUSION: The majority of prognostic scores were relevant for patients with BM from BC in our independent population, and the Nieder score seems to present the best predictive value but showed a relatively low positive predictive value. Thus, these results remain insufficient and challenge the routine use of these scoring systems.
Entities:
Keywords:
brain metastases; breast cancer; prognostic scores
Authors: David G Kirsch; Carlos J Ledezma; Christina S Mathews; Atul K Bhan; Marek Ancukiewicz; Fred H Hochberg; Jay S Loeffler Journal: J Clin Oncol Date: 2005-03-20 Impact factor: 44.544
Authors: D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton Journal: N Engl J Med Date: 2001-03-15 Impact factor: 91.245
Authors: R A Patchell; P A Tibbs; J W Walsh; R J Dempsey; Y Maruyama; R J Kryscio; W R Markesbery; J S Macdonald; B Young Journal: N Engl J Med Date: 1990-02-22 Impact factor: 91.245
Authors: L Gaspar; C Scott; M Rotman; S Asbell; T Phillips; T Wasserman; W G McKenna; R Byhardt Journal: Int J Radiat Oncol Biol Phys Date: 1997-03-01 Impact factor: 7.038
Authors: Jill S Barnholtz-Sloan; Andrew E Sloan; Faith G Davis; Fawn D Vigneau; Ping Lai; Raymond E Sawaya Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: Paul D Brown; Jan C Buckner; Judith R O'Fallon; Nancy L Iturria; Brian P O'Neill; Cerise A Brown; Bernd W Scheithauer; Robert P Dinapoli; Robert M Arusell; Walter J Curran; Ross Abrams; Edward G Shaw Journal: Int J Radiat Oncol Biol Phys Date: 2004-05-01 Impact factor: 7.038
Authors: Christina A Meyers; Jennifer A Smith; Andrea Bezjak; Minesh P Mehta; James Liebmann; Tim Illidge; Ian Kunkler; Jean-Michel Caudrelier; Peter D Eisenberg; Jacobus Meerwaldt; Ross Siemers; Christian Carrie; Laurie E Gaspar; Walter Curran; See-Chun Phan; Richard A Miller; Markus F Renschler Journal: J Clin Oncol Date: 2004-01-01 Impact factor: 44.544
Authors: Paul W Sperduto; Norbert Kased; David Roberge; Samuel T Chao; Ryan Shanley; Xianghua Luo; Penny K Sneed; John Suh; Robert J Weil; Ashley W Jensen; Paul D Brown; Helen A Shih; John Kirkpatrick; Laurie E Gaspar; John B Fiveash; Veronica Chiang; Jonathan P S Knisely; Christina Maria Sperduto; Nancy Lin; Minesh Mehta Journal: J Neurooncol Date: 2013-03-06 Impact factor: 4.130
Authors: Elena Laakmann; Kerstin Riecke; Yvonne Goy; Jan F Kersten; Andreas Krüll; Volkmar Müller; Cordula Petersen; Isabell Witzel Journal: J Cancer Res Clin Oncol Date: 2015-09-30 Impact factor: 4.553
Authors: Nitesh Rohatgi; A Munshi; P Bajpai; M Singh; S Sahai; M Ahmad; K Singh; H Singh; Purvish M Parikh; S Aggarwal Journal: South Asian J Cancer Date: 2018 Apr-Jun